Medline priced an upsized offering of 216,034,482 shares at $29 each in December 2025, raising about $6.26 billion before underwriting expenses and making it one of the largest U.S. initial public offerings in years.
The shares rose about 30% in their first session. That first-day gain showed that investors were willing to fund a large, established health-care supplier, but it also meant public buyers valued the company well above the price accepted by the selling shareholders.
This article is a retrospective benchmark. It should not be read as a claim that Medline listed in August 2026 or that current IPO conditions are identical to those at its debut.
“IPO market expected to accelerate”
— a market analyst commenting on the Medline debut
What the debut did—and did not—prove
A successful large offering can encourage other issuers, but the market does not reopen all at once. Profitability, leverage, sector, valuation and broader volatility still determine whether each deal can clear.
The next evidence
The stronger test is performance after listing: quarterly cash flow, debt reduction, margins and trading after insider lockups. Those measures show whether initial demand was supported by durable operating results.
What an IPO pop does—and does not—measure
A strong first-day gain shows that public investors were willing to pay more than the offering price once trading began. It can also suggest that bankers priced the deal conservatively to ensure demand. Neither interpretation proves that the business will compound value over time: the more durable tests are revenue quality, margins, cash generation, leverage, and how the company uses the capital raised.
Medline is especially useful as a benchmark because its size and private-equity history made the deal harder to dismiss as a small speculative listing. Future issuers can point to the debut when testing demand, but they will still be judged on their own debt loads and earnings. Readers should treat the 30% jump as evidence about market appetite on that date, not as a standing recommendation or a guarantee for the next offering.
Next checkpoint
What to watch
Medline's first public earnings reports, debt reduction, post-lockup trading and whether other large issuers follow successfully.
Evidence
Sources and editorial notes
This post was reviewed against the linked primary material and independent sources. Developing figures are labeled and may change.
Spot an error? Read our corrections policy.
